will splint the diaphragm and cause cardiorespiratory failure and death. Some patients require postoperative ventilation. In 1940, Moreno reported induction of pneumoperitoneum, by intermittent insufflation of air, to enlarge the abdominal cavity before surgery1, and various modifications of this technique have since been used2'3. Apart from lessening the effective diaphragmatic splinting, this method can make a hernia easier to reduce, with less tension on the repair; other advantages are said to be gradual lysis of adhesions between the hernia contents and ring, and a reduction of mesenteric and omental oedema4. The disadvantages include a long preoperative stay (average 9 days)5, haematoma formation, organ perforation, subcutaneous and mediastinal emphysema4'5 and venous embolism6.
Stoppa7 advocates the use of preoperative pneumoperitoneum in the management of all 'monstrous' or 'voluminous' abdominal hernias, along with ventilatory physiotherapy. We feel, however, that in healthy patients there is insufficient evidence for its routine use. In a series of 65 giant hernia repairs without the use of mesh, in patients free of chronic disease, Badejo reported no major complications or deaths; nor, after 1-5 years, were there any recurrences8. In healthy patients, repair can be efficiently achieved with conventional methods carefully applied. Gastrointestinal tract involvement in type-I neurofibromatosis usually takes the form of a stromal tumourl. Diffuse ganglioneuromatosis of the small intestine is a rare feature.
CASE HISTORY
A man aged 64 with known type-i neurofibromatosis (multiple cafe-au-lait macules, cutaneous neurofibromata and a family history) had experienced worsening colicky abdominal pain, exacerbated by eating, for the past year. He also complained of diarrhoea, steatorrhoea, nausea and anorexia and had lost nearly 10 kg over six weeks. 2 years earlier he had undergone two laparotomies for massive rectal bleeding, at which three neurofibromata had been resected from the jejunum. In the same year he had an episode of obstructive jaundice which resolved with medical treatment; computed tomography revealed chronic pancreatitis. On examination, he was cachectic and had a 10 x 8 cm hard fixed mass in the right iliac fossa. Routine blood tests were normal apart from liver function tests suggesting posthepatic obstruction. Abdominal radiography showed dilatation of the small bowel, apparently due to extrinsic compression ( Figure 1 ). On computed tomography there were thickened and matted small bowel loops from the head of the pancreas to the caecum and barium enema revealed an ulcerated and oedematous bowel. The differential diagnosis included recurrent neurofibromatosis, sarcomatous change within neurofibromata, inflammatory mass secondary to pancreatitis or a new diagnosis of Crohn's disease. On gastroscopy there was gastritis, duodenitis and a hiatus hernia. Ultrasound showed a calcified gallbladder and dilatation of the common bile duct which retrograde cholangiopancreatography indicated was due to extrinsic compression.
At laparotomy the mass within the right iliac fossa was seen to consist of matted loops of small bowel and caecum around irregular thickened mesentery. In addition, a 2 x 1 cm lesion was identified compressing the lower end of the common bile duct. The large mass was excised en-bloc with the associated small bowel loops and, on opening, showed diffuse thickening of the small intestine with a discrete polyp ( Figure 2 ). The mass adjacent to the common bile duct was also excised. Histological examination revealed diffuse ganglioneuromatosis of the small bowel and appendix with neuronal hyperplasia and occasional small plexiform neurofibromata in the mesentery. Tissue from around the common bile duct contained a large reactive lymph node. The patient was symptom-free 23 months later. COMMENT Neurofibromatosis, originally described by von Recklinghausen as a single disease2, is now known to be two clinically and genetically distinct diseases3. Type 1, or peripheral neurofibromatosis, is more common than type 2, or bilateral acoustic neurofibromatosis. Gastrointestinal tract involvement is seen in only 10-25% of patients with neurofibromatosis type 14X5 and causes symptoms in under 5%6. Occasionally it affects the small intestine exclusively, without any extraintestinal manifestations7. However, this latter autosomal dominant inherited syndrome seems to be distinct from von Recklinghausen's disease. Gastrointestinal involvement occurs in three main pathological formsl neuronal hyperplasia ranging in severity from subtle Neuronal hyperplasia may involve the mucosa and be accompanied by ganglion cells, so-called ganglioneuromatosis, the cause of the mass in our patient. However, ganglioneuromatosis is not restricted to neurofibromatosis and has been described in other conditions such as multiple endocrine neoplasia 2b8. The majority of clinically overt gastrointestinal tumours arise in the upper gastrointestinal tract, either in the stomach or in the jejunum (as initially in our case), causing obstruction, volvulus, intussusception, haemorrhage or perforation. In contrast, colorectal or appendiceal tumours are rare9. The duodenal carcinoid tumours in neurofibromatosis type 1 have a distinctive glandular architecture, contain psammoma bodies and produce somatostatin1; they were not seen in our patient.
Surgery in type-I neurofibromatosis is usually reserved for tumorous lesions that are large, painful or located in strategic areas where continued expansion would compromise organ function. Recurrences occasionally follow attempts at complete excision because of the ill-defined nature of neurofibromata. Malignant transformation of tumours is described in 2% of patients with type 1 neurofibromatosis10. Pain or rapid enlargement of a lesion should arouse suspicion of sarcomatous change. Flavoxate hydrochloride is a smooth-muscle antispasmodic with additional analgesic and local anaesthetic properties. It is indicated for symptomatic relief of urinary tract muscle spasm in the absence of urinary obstruction. The drug is well tolerated1-3, with few side-effects other than those due to its antimuscarinic actions.
A man aged 81 who had been taking 200mg flavoxate (Urispas 200) three times daily for three months was referred with a two-week history of painless jaundice, anorexia and fatigue. Previously he had been well. There were no risk factors for viral hepatitis and he had not been taking other drugs. He drank up to half a bottle of wine per day and had done so for many years. His only medical history of note was a prostatectomy two years earlier, with a few foci of adenocarcinoma cells in the resected tissue. On examination he was deeply jaundiced; lymphadenopathy, enlargement of the liver or spleen, and stigmata of chronic liver disease were absent.
Blood results were as follows: bilirubin 527 /imol/L, aspartate aminotransferase 923 U/L, alanine aminotransferase 1474 U/L, alkaline phosphatase 146 U/L, gamma glutamyl transferase 772 U/L, albumin 35 g/L, prothrombin time 15 s (control 13 s) and activated partial thromboplastin time 50s (control 41 s), full blood count within normal limits. An ultrasound scan of the liver and biliary tree showed nothing abnormal. Blood was IgG antibody positive but IgM antibody negative for hepatitis A, indicating previous but not recent infection. Hepatitis B surface antigen was negative, as were antibodies to cytomegalovirus and Epstein-Barr virus. Antinuclear, antismooth-muscle, anti-mitochondrial and anti-liver/kidney microsomal antibodies were all negative. Hepatitis C antibody checked six months after his jaundice was also negative. These findings were all consistent with a hepatitic illness and excluded an obstructive jaundice. The patient was asked to stop taking flavoxate. Over a period of months his jaundice resolved and his liver function tests completely returned to normal. He returned to full health and was not rechallenged with the drug. COMMENT The manufacturers and the Committee on Safety of Medicine have received ten reports of deranged liver biochemistry associated with flavoxate (personal communications). Several of the patients had a hepatitis-like biochemical picture similar to that in our patient. In many of these cases the patients were taking other drugs and to our knowledge ours is the first report of hepatitis related to monotherapy with flavoxate. Although our patient was not rechallenged with the drug, the temporal association between the jaundice and the medication leads us to suspect that flavoxate was the cause of his jaundice.
